自动瞳孔测量评估非惊厥性癫痫持续状态治疗成功
这项前瞻性观察研究对68次NCSE发作进行系列自动瞳孔测量,患者按当地标准阶梯式接受氯硝西泮(1-2 mg)、左乙拉西坦(40 mg/kg)和拉考沙胺(5 mg/kg)治疗,持续脑电图监测至NCSE终止。97.1%的发作成功终止,16.2%为难治性;85.3%的发作基线minNPi≤4.0。NCSE终止后minNPi显著升高(p<0.001,Cohen's d=1.24,95%CI 0.88-1.61)。氯硝西泮无反应者基线minNPi高于有反应者(p=0.008),有反应者minNPi升高而无反应者不升高。难治性与正常基线minNPi、男性及更长NCSE持续时间相关。
要点
- 在68次NCSE发作中,85.3%基线minNPi≤4.0;NCSE终止后minNPi显著升高(p<0.001,d=1.24,95%CI 0.88-1.61)。
- 氯硝西泮无反应者基线minNPi高于有反应者(p=0.008);有反应者治疗后minNPi升高(p<0.001),无反应者不升高。
- 难治性NCSE(16.2%)与正常基线minNPi、男性及更长NCSE持续时间相关(主成分分析,成分1解释32.6%方差,r=0.78;成分2解释27.1%方差,r=0.62和r=0.78)。
- 该研究采用阶梯方案:氯硝西泮1-2 mg、左乙拉西坦40 mg/kg、拉考沙胺5 mg/kg,持续脑电图监测下进行,难治者接受个体化方案。
- 自动瞳孔测量可能作为NCSE治疗反应的无创神经监测辅助工具,但样本量68次发作,需进一步验证。
适用人群与场景
- 68次非惊厥性癫痫持续状态(NCSE)发作,患者接受持续脑电图监测和阶梯抗癫痫治疗;排除人群原文未提及。
诊断标准与关键阈值
- NCSE诊断依据原文未提及具体标准;基线minNPi≤4.0定义为异常(原文提及85.3%发作基线minNPi≤4.0)。
- NPi通过自动瞳孔测量双侧评估,取较低侧为minNPi,在每步治疗前后测量。
处置流程与药物剂量
- 第一步:氯硝西泮1-2 mg(原文未注明途径和频次)。
- 第二步:左乙拉西坦40 mg/kg(原文未注明途径和频次)。
- 第三步:拉考沙胺5 mg/kg(原文未注明途径和频次)。
- 上述药物按阶梯方案在持续脑电图监测下使用直至NCSE终止;难治性NCSE接受个体化方案(原文未详述)。
- 每步治疗前后进行双侧自动瞳孔测量,取minNPi用于评估。
红旗征与不能漏的情况
- 难治性NCSE:原文定义16.2%发作为难治性,与正常基线minNPi、男性及更长NCSE持续时间相关;需个体化治疗。
- 氯硝西泮无反应:基线minNPi较高者更可能无反应(p=0.008),且治疗后minNPi不升高。
研究设计与关键结果
- 研究类型:前瞻性观察研究;样本量:68次NCSE发作;中心数原文未提及。
- 干预:阶梯式氯硝西泮(1-2 mg)、左乙拉西坦(40 mg/kg)、拉考沙胺(5 mg/kg)治疗,持续脑电图监测;主要观察NPi变化与治疗反应。
- 主要结果:97.1%发作NCSE终止,16.2%难治;NCSE终止后minNPi显著升高(p<0.001),Cohen's d=1.24(95%CI 0.88-1.61)。
- 次要结果:氯硝西泮无反应者基线minNPi高于有反应者(p=0.008);有反应者minNPi升高(p<0.001),无反应者不升高;难治性与正常基线minNPi、男性、更长NCSE持续时间相关(主成分分析成分1方差32.6%,r=0.78;成分2方差27.1%,r=0.62和r=0.78)。
证据类型、等级与局限
- 证据类型:前瞻性观察研究(单中心?原文未提及中心数);样本量68次发作,非随机、无对照干预比较;证据等级原文未提及。
- 局限:观察性设计,样本量较小,中心数未提及,NPi测量时机与治疗步骤绑定,难治性分析为主成分分析推导,需前瞻性验证。
对床旁实践的改变
- 在NCSE患者中,可考虑用自动瞳孔测量监测minNPi:基线minNPi≤4.0常见,NCSE终止后minNPi升高可能提示治疗成功。
- 基线minNPi较高者可能对氯硝西泮反应不佳,正常基线minNPi与难治性NCSE相关,提示需更积极评估和治疗。
- 该工具为无创辅助监测,不能替代持续脑电图;原文未提供NPi指导治疗的阈值或随机对照证据,不改变现有阶梯治疗方案。
指南或共识出处
- 原文未提及指南或共识名称;来源期刊:Neurocrit Care。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Altered pupillary function may reflect nonconvulsive status epilepticus (NCSE). Neurological pupil index (NPi) assessed by automated pupillometry is a surrogate marker of global pupillary function. We aimed to assess NPi changes in relation to NCSE treatment response.
METHODS: In this prospective observational study, serial automated pupillometry was performed in 68 NCSE episodes. In accordance with local standards, patients were treated with clonazepam (1-2 mg), levetiracetam (40 mg/kg), and lacosamide (5 mg/kg) in a stepwise approach under continuous electroencephalography monitoring until NCSE was terminated. Patients with refractory NCSE received individualized regimens. NPi was assessed bilaterally before and after each treatment step. For statistical analysis, the lower NPi of both sides (minNPi) was used. Nonparametric testing for matched samples and Cohen's d to estimate effect size were performed. Principal component analysis was applied to assess the contribution of baseline minNPi, age, sex, and NCSE duration to treatment outcome.
RESULTS: In 97.1% of 68 episodes, NCSE could be terminated; in 16.2%, NCSE was refractory. In 85.3% of episodes, an abnormal baseline minNPi ≤ 4.0 was obtained. After NCSE termination, minNPi increased significantly (p < 0.001). Cohen's d showed a strong effect size of 1.24 (95% confidence interval 0.88-1.61). Baseline minNPi was higher in clonazepam nonresponders vs. responders (p = 0.008), minNPi increased in responders (p < 0.001) but not in nonresponders. NCSE refractivity was associated with normal baseline minNPi (principal component analysis, component 1, 32.6% of variance, r = 0.78), male sex, and longer NCSE duration (component 2, 27.1% of variance, r = 0.62 and r = 0.78, respectively).
CONCLUSIONS: Automated pupillometry may be a helpful noninvasive neuromonitoring tool for the assessment of patients with NCSE and response to treatment.
参考来源
- Godau J, Bharad K, Rösche J, et al. Automated Pupillometry for Assessment of Treatment Success in Nonconvulsive Status Epilepticus. Neurocrit Care. 2021. PMID: 34331202. doi:10.1007/s12028-021-01273-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。